We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Tm Bioscience and Luminex Extend Partnership

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Tm Bioscience and Luminex Extend Partnership "

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Tm Bioscience Corporation and Luminex® Corporation have announced that they have signed a multi-year extension of their partnership agreement, which grants Tm rights to commercialize DNA-based molecular diagnostics that operate on Luminex's xMAP® technology platform.

All genetic tests from Tm Bioscience are based on the Tag-It™ Universal Array platform, which utilizes a proprietary universal tag system that allows for easy optimization, product development and expansion.

Assays from Tm utilize the Luminex xMAP technology platform, the industry benchmark for bead based bioassay multiplexing.

Combined, the Universal Array and Luminex instrument are a best in class solution for performing clinical grade multiplexed genetic tests.

The original agreement between Tm Bioscience and Luminex expires on March 28, 2006. The renegotiated agreement incorporates similar terms to the original agreement, including the ability for Tm to distribute Luminex's xMAP systems such as the LX200 instrument.

"In 2001, we selected Luminex as a platform partner, having determined that a key factor for our success would be to commercialize our tests on an instrument capable of penetrating the clinical laboratory market," said Greg Hines, president and chief executive officer of Tm Bioscience Corporation.

"Now, with more than 3400 instrument placements in life science laboratories worldwide, including a large number of clinical laboratories, Luminex is well positioned and the market reach they have achieved is a solid foundation for the further growth of our company."

"Tm Bioscience is helping drive our success, having commercialized a broad menu of genetic tests and reagents optimized to run on the Luminex xMAP system, including the first multiplexed human disease genotyping test to be cleared by the U.S. Food and Drug Administration (FDA) for diagnostic use in the United States," said Patrick J. Balthrop, president and chief executive officer of Luminex Corporation.

"Molecular diagnostics is an important growth market for Luminex and we are pleased to extend our successful relationship with Tm."